The patient blood interface
Blood performs the essential functions of transport (eg oxygen), regulation (eg of pH, temperature etc) and is central to the body’s defence mechanism. Hence any quantitative and/or functional defect of the patient’s blood, or in the transfused blood product may compromise patient outcome.
We have a series of studies investigating how anaemia and bleeding compromises the outcomes of orthopaedic patients, elderly emergency patients and pregnant women. To improve the outcomes of these patients we are developing processes to rapidly identify the risk and cause of bleeding, so that they can be addressed earlier. In another study we are comparing the clinical, social and economic impact of patient administered subcutaneous immunoglobulin (SCIg) to hospital based intravenous immunoglobulin (IVIg). Both of which are expensive and in limited supply in Australia.
This team is focussed on translational research relating to the Patient and Blood Interface. To achieve this we work with the hospital patient blood management committees of the Sunshine Coast Hospital and Health Service (SCHHS) and The Prince Charles Hospital (TPCH), to support and promote evidence based transfusion medicine practice, and welcome more collaborations in this area.
Obesity and diabetes research
Theme Leader: Dr Mark Hayes, Adjunct Fellow – Obesity and Diabetes Group
Tel: +61 7 5456 3466
Type 2 Diabetes Mellitus (T2DM) has reached epidemic proportions with the world incidence projected to rise from 382 million in 2013 to 592 million in 2035. Burgeoning rates of obesity and a more sedentary lifestyle have combined to produce an epidemic of Type 2 diabetes mellitus (T2DM) which has the capacity to severely strain or overwhelm the health care system over the next decade. The incidence of T2DM increased by 10% between 2013 and 2015 on the Sunshine Coast and the cost to the health care system may rise 5 fold over the next three decades. The number of people with undiagnosed diabetes, prediabetes or diabetes risk could be 3 times the number who have been currently diagnosed. Urgent action is required to prevent the progression of diabetes in individuals in our community. This needs to be based on a multi-disciplinary approach which combines early identification of those at risk of disease, a wellness program to minimize lifestyle factors which contribute to progression, contributions from the specialties which treat the major co-morbidities, nursing and GP education and involvement in treatment and outreach and basic research into the root causes of the disease which are currently poorly understood.
I have a number of potential projects particularly involving liver genes which may contribute to the dysregulation of liver glycemic homeostasis or act as early biomarkers for risk of the development of metabolic syndrome, Type 2 Diabetes and heart disease. If you are interested in these areas contact Dr Mark Hayes on Tel: +61 7 5456 3466 or Email: email@example.com.